文献速递前列腺癌

恩扎卢胺联合雄激素剥夺治疗在寡转移性激素敏感性前列腺癌中的疗效:ARCHES试验的事后分析

The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
PubMed 文献 · Eur Urol · 2023-05-12

本研究为ARCHES试验事后分析,纳入927例非内脏转移性激素敏感性前列腺癌患者,随机接受恩扎卢胺(160 mg/d口服)联合ADT或安慰剂联合ADT。恩扎卢胺联合ADT在寡转移和广泛转移患者中均改善影像学无进展生存和总生存,安全性总体相似。

要点

  • 恩扎卢胺联合ADT改善寡转移患者rPFS(HR 0.27)和OS(HR 0.59)。
  • 恩扎卢胺联合ADT改善广泛转移患者rPFS(HR 0.33)和OS(HR 0.55)。
  • 各亚组安全性特征总体相似,局限性包括少于3个转移灶患者数量少。

核心结论

  • 事后分析表明恩扎卢胺的效用不受转移负荷或寡转移疾病类型影响,并提示早期强化系统强效雄激素受体抑制治疗具有优势。

研究设计与样本

  • ARCHES试验(NCT02677896)的事后分析,纳入927例非内脏转移性激素敏感性前列腺癌患者,随机1:1接受恩扎卢胺(160 mg/d口服)联合ADT或安慰剂联合ADT,按寡转移(1-5个转移灶)或广泛转移(≥6个转移灶)分类。

主要发现

  • 寡转移患者中,恩扎卢胺联合ADT较安慰剂联合ADT改善rPFS(HR 0.27,95% CI 0.16-0.46;p < 0.001)和OS(HR 0.59,95% CI 0.40-0.87;p < 0.005)。
  • 广泛转移患者中,恩扎卢胺联合ADT较安慰剂联合ADT改善rPFS(HR 0.33,95% CI 0.23-0.46;p < 0.001)和OS(HR 0.55,95% CI 0.41-0.74;p < 0.001)。
  • 各亚组安全性特征总体相似。

临床怎么用

  • 作者认为,无论转移负荷或寡转移疾病类型如何,恩扎卢胺均显示效用,并提示早期强化系统强效雄激素受体抑制治疗具有优势。

局限性

  • 局限性包括少于3个转移灶的患者数量少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few phase 3 studies have evaluated optimal systemic treatment strategies for patients with oligometastatic hormone-sensitive prostate cancer (HSPC), who may be at risk of undertreatment. OBJECTIVE: To evaluate outcomes for patients with oligometastatic and polymetastatic HSPC treated with enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of data for 927 patients with nonvisceral metastatic HSPC in the ARCHES trial (NCT02677896). INTERVENTION: Patients were randomized 1:1 to enzalutamide (160 mg/d orally) plus ADT or placebo plus ADT with HSPC categorized as oligometastatic (1-5 metastases) or polymetastatic (≥6 metastases). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The treatment effect on radiographic progression-free survival (rPFS), overall survival (OS), and secondary efficacy endpoints was evaluated in terms of the number of metastases. Safety was assessed. Cox proportional hazards models were used to generate hazard ratios (HRs). The Brookmeyer and Crowley method was used to generate 95% confidence intervals (CIs) for Kaplan-Meier median values. RESULTS AND LIMITATIONS: Enzalutamide plus ADT improved rPFS (HR 0.27, 95% CI 0.16-0.46; p < 0.001), OS (HR 0.59, 95% CI 0.40-0.87; p < 0.005), and secondary endpoints in patients with oligometastatic or polymetastatic disease (rPFS: HR 0.33, 95% CI 0.23-0.46; p < 0.001; OS: HR 0.55, 95% CI 0.41-0.74; p < 0.001). Safety profiles were generally similar across subgroups. Limitations include the small numbers of patients with fewer than three metastases. CONCLUSIONS: This post hoc analysis demonstrated the utility of enzalutamide, irrespective of metastatic burden or type of oligometastatic disease, and suggests that earlier treatment intensification with systemic potent androgen receptor inhibition is advantageous. PATIENT SUMMARY: This study considered two treatment options for metastatic hormone-sensitive prostate cancer in patients with one to five metastases or six or more metastases. Treatment with enzalutamide plus ADT improved survival and other outcomes over ADT alone, whether patients had few or many metastases.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Armstrong AJ, Iguchi T, Azad AA, et al. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol. 2023. PMID: 37179240. doi:10.1016/j.eururo.2023.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。